SCHEMBL20119932

SCHEMBL20119932

CSc1nc2c(NCc3ccncn3)nc(Cl)nc2[nH]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 1/20 0.36
CDK2 P24941 3/20 0.32
CDK1 P06493 2/20 0.32
CCNE1 P24864 2/20 0.32
JAK2 O60674 1/20 0.32
IGF1R P08069 1/20 0.32
PIM1 P11309 1/20 0.32
SRC P12931 1/20 0.32
CSNK2A2 P19784 1/20 0.32
KCNA5 P22460 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
FLT4 P35916 1/20 0.32
FLT3 P36888 1/20 0.32
MAP3K8 P41279 1/20 0.32
CSNK1A1 P48729 1/20 0.32
GSK3B P49841 1/20 0.32
JAK3 P52333 1/20 0.32
PLK1 P53350 1/20 0.32
CSNK2A1 P68400 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119926 0.83 KCNH3 (0.37) KCNH3CDK2CDK1CCNE1JAK2
SCHEMBL20119803 0.82 CDK2 (0.36) KCNH3CDK2CDK1CCNE1JAK2
SCHEMBL20119820 0.81 KCNH3 (0.36) KCNH3CDK2CDK1CCNE1JAK2
SCHEMBL25873886 0.81 KCNH3 (0.37) KCNH3CDK2CDK1CCNE1JAK2
SCHEMBL20119933 0.79 CHRM4 (0.39) KCNH3CDK2CCNE1JAK2IGF1R
SCHEMBL20119710 0.79 KCNH3 (0.34) KCNH3CDK2CDK1CCNE1JAK2
SCHEMBL20119762 0.79 PDE10A (0.36) KCNH3CDK2CCNE1JAK2IGF1R
SCHEMBL20120003 0.78 KCNH3 (0.34) KCNH3CDK2CDK1CCNE1JAK2
SCHEMBL20119693 0.77 KCNH3 (0.40) KCNH3CDK2CDK1CCNE1JAK2
SCHEMBL20119702 0.77 JAK2 (0.35) KCNH3CDK2CCNE1JAK2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885CDK2 3622/4885CDK1 3620/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885CDK2 3622/4885CDK1 3620/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885CDK2 3622/4885CDK1 3620/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885CDK2 3622/4885CDK1 3620/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885CDK2 3622/4885CDK1 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.